CCM Investment Advisers LLC Decreases Stock Holdings in AbbVie Inc. $ABBV

CCM Investment Advisers LLC reduced its position in shares of AbbVie Inc. (NYSE:ABBV) by 9.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 73,838 shares of the company’s stock after selling 7,585 shares during the period. AbbVie accounts for approximately 1.7% of CCM Investment Advisers LLC’s portfolio, making the stock its 22nd largest position. CCM Investment Advisers LLC’s holdings in AbbVie were worth $17,097,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of ABBV. TD Capital Management LLC grew its position in shares of AbbVie by 82.9% in the 1st quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after buying an additional 58 shares during the last quarter. Marshall & Sullivan Inc. WA purchased a new stake in AbbVie in the second quarter worth $25,000. Evolution Wealth Management Inc. bought a new stake in AbbVie in the second quarter valued at $26,000. Spurstone Advisory Services LLC bought a new stake in AbbVie in the second quarter valued at $28,000. Finally, Financial Gravity Companies Inc. purchased a new position in AbbVie during the 2nd quarter valued at $36,000. 70.23% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Wells Fargo & Company raised their target price on shares of AbbVie from $240.00 to $260.00 and gave the stock an “overweight” rating in a research report on Friday, September 12th. Piper Sandler reaffirmed an “overweight” rating and set a $289.00 price objective (up from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. Bank of America upped their target price on AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Guggenheim raised their target price on AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research note on Monday, October 20th. Finally, Scotiabank began coverage on AbbVie in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price target on the stock. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $245.84.

AbbVie Stock Up 2.1%

Shares of NYSE:ABBV opened at $227.44 on Monday. The company has a current ratio of 0.72, a quick ratio of 0.60 and a debt-to-equity ratio of 44.14. The stock has a fifty day simple moving average of $226.63 and a two-hundred day simple moving average of $211.31. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The stock has a market capitalization of $401.98 billion, a price-to-earnings ratio of 172.30, a PEG ratio of 1.29 and a beta of 0.36.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The firm had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company’s quarterly revenue was up 9.1% on a year-over-year basis. During the same period in the prior year, the firm posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio (DPR) is 496.97%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.